Universe Pharmaceuticals (NASDAQ:UPC) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Universe Pharmaceuticals (NASDAQ:UPC) to a hold rating in a research note issued to investors on Saturday morning.

Separately, Weiss Ratings upgraded shares of Universe Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

Universe Pharmaceuticals Stock Down 2.8%

Shares of UPC stock opened at $4.90 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.90 and a current ratio of 4.05. Universe Pharmaceuticals has a twelve month low of $2.00 and a twelve month high of $17.96. The business has a fifty day simple moving average of $5.08 and a 200 day simple moving average of $3.67.

Universe Pharmaceuticals (NASDAQ:UPC) last posted its earnings results on Wednesday, July 29th. The company reported ($1.38) EPS for the quarter. The firm had revenue of $4.52 million for the quarter.

About Universe Pharmaceuticals

Universe Pharmaceuticals, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for ocular diseases. The company’s primary research efforts center on small-molecule compounds designed to address unmet needs in glaucoma, ocular hypertension and post-surgical ocular inflammation. By leveraging targeted enzyme inhibition and proprietary formulation technologies, Universe aims to bring forward topically administered medications that combine efficacy with an improved safety profile versus existing treatments.

The company’s lead candidate, UPC-1001, has been advanced into clinical trials for the treatment of open-angle glaucoma and ocular hypertension, where it seeks to lower intraocular pressure through a unique mechanism of action.